Literature DB >> 1698476

CD34+ hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus.

D von Laer1, F T Hufert, T E Fenner, S Schwander, M Dietrich, H Schmitz, P Kern.   

Abstract

Hematologic abnormalities occur in the majority of patients with acquired immunodeficiency syndrome (AIDS). Infection of the hematopoietic progenitor cells has been proposed as a potential explanation. In this study, different bone marrow cell populations, including the CD34+ hematopoietic progenitor cells, were purified by a fluorescence-activated cell sorter (FACS) and analyzed for the presence of human immunodeficiency virus-1 (HIV-1) proviral DNA using the polymerase chain reaction. A group of 14 patients with AIDS or AIDS-related complex (ARC) was studied (11 with peripheral blood cytopenias). The CD4+ helper cells in the bone marrow were found positive for HIV-1 DNA in all patients. In contrast, CD34+ progenitor cells were positive in only one patient. Two monocyte samples and two samples of CD4-/CD34- lymphocytes/blasts (mainly B and CD8 lymphocytes) were positive. Proviral DNA could not be detected in granulocytes. FACS analysis showed that the percentage of CD34+ hematopoietic progenitor cells was not altered in the bone marrow of AIDS patients in comparison with the HIV-1 seronegative controls. In contrast, the number of CD4+ lymphocytes was markedly reduced in the bone marrow of AIDS patients. These results show that the hematologic abnormalities in AIDS patients are neither explained by direct infection of the hematopoietic progenitor cells with HIV-1 nor by a depletion of progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698476

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  An intrinsic host defense against HIV-1 integration?

Authors:  Paul D Bieniasz
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

2.  Primitive hematopoietic cells resist HIV-1 infection via p21.

Authors:  Jielin Zhang; David T Scadden; Clyde S Crumpacker
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

Review 3.  Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages.

Authors:  Davide Gibellini; Alberto Clò; Silvia Morini; Anna Miserocchi; Cristina Ponti; Maria Carla Re
Journal:  World J Virol       Date:  2013-05-12

4.  Diagnosis of human cytomegalovirus-induced retinitis in human immunodeficiency virus type 1-infected subjects by using the polymerase chain reaction.

Authors:  T E Fenner; J Garweg; F T Hufert; M Boehnke; H Schmitz
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

5.  Early and persistent bone marrow hematopoiesis defect in simian/human immunodeficiency virus-infected macaques despite efficient reduction of viremia by highly active antiretroviral therapy during primary infection.

Authors:  H Thiebot; F Louache; B Vaslin; T de Revel; O Neildez; J Larghero; W Vainchenker; D Dormont; R Le Grand
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  The impaired number of circulating granulocyte/macrophage progenitors (CFU-GM) in human immunodeficiency virus-type 1 infected subjects correlates with an active HIV-1 replication.

Authors:  M C Re; G Zauli; G Furlini; S Ranieri; P Monari; E Ramazzotti; M La Placa
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

7.  Wild-type equine infectious anemia virus replicates in vivo predominantly in tissue macrophages, not in peripheral blood monocytes.

Authors:  D C Sellon; S T Perry; L Coggins; F J Fuller
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

Review 9.  The use of GM-CSF in AIDS.

Authors:  D T Scadden
Journal:  Infection       Date:  1992       Impact factor: 3.553

10.  HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

Authors:  Maud Mavigner; Pierre Delobel; Michelle Cazabat; Martine Dubois; Fatima-Ezzahra L'faqihi-Olive; Stéphanie Raymond; Christophe Pasquier; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.